男性不育症的个性化生物标志物

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-09-22 DOI:10.1016/j.cca.2025.120623

Ali Parvin , Mohammad Mehdi Shadravan , Sonia Sadeghpour , Mortaza Taheri-Anganeh , Hojat Ghasemnejad-Berenji

{"title":"男性不育症的个性化生物标志物","authors":"Ali Parvin , Mohammad Mehdi Shadravan , Sonia Sadeghpour , Mortaza Taheri-Anganeh , Hojat Ghasemnejad-Berenji","doi":"10.1016/j.cca.2025.120623","DOIUrl":null,"url":null,"abstract":"<div><div>Male-related factors account for 30% of infertility cases and contribute an additional 20% when combined with female infertility factors. Consequently, it is crucial to diagnose, predict, and develop innovative strategies to tackle male infertility. The evaluation of male infertility extends beyond medical history and physical examination, with a primary focus on semen analysis (SA) and endocrine assessment. SA assesses various macroscopic semen parameters such as volume, pH, color, and viscosity. Because of the significant variability in these parameters, a range of complementary biomarkers has been introduced over time. The limited effectiveness of traditional biomarkers in identifying the underlying causes of male infertility has driven the search for more accessible, cost-effective, and predictive markers of reproductive outcomes. The emerging field of omics, which includes genomic, proteomic, and metabolomic biomarkers, offers a promising pathway for targeted diagnostics in male infertility. This review aims to highlight the significance of biomarkers in male infertility. Given the limitations of conventional diagnostic techniques, biomarkers provide valuable insights into the underlying causes of male infertility and potential pathways for personalized treatment. The review discusses the definition, prevalence, and etiology of male infertility, followed by an examination of various types of biomarkers, including proteomic, genomic, epigenetic, and metabolomic markers.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"579 ","pages":"Article 120623"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Personalized biomarkers in male infertility\",\"authors\":\"Ali Parvin , Mohammad Mehdi Shadravan , Sonia Sadeghpour , Mortaza Taheri-Anganeh , Hojat Ghasemnejad-Berenji\",\"doi\":\"10.1016/j.cca.2025.120623\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Male-related factors account for 30% of infertility cases and contribute an additional 20% when combined with female infertility factors. Consequently, it is crucial to diagnose, predict, and develop innovative strategies to tackle male infertility. The evaluation of male infertility extends beyond medical history and physical examination, with a primary focus on semen analysis (SA) and endocrine assessment. SA assesses various macroscopic semen parameters such as volume, pH, color, and viscosity. Because of the significant variability in these parameters, a range of complementary biomarkers has been introduced over time. The limited effectiveness of traditional biomarkers in identifying the underlying causes of male infertility has driven the search for more accessible, cost-effective, and predictive markers of reproductive outcomes. The emerging field of omics, which includes genomic, proteomic, and metabolomic biomarkers, offers a promising pathway for targeted diagnostics in male infertility. This review aims to highlight the significance of biomarkers in male infertility. Given the limitations of conventional diagnostic techniques, biomarkers provide valuable insights into the underlying causes of male infertility and potential pathways for personalized treatment. The review discusses the definition, prevalence, and etiology of male infertility, followed by an examination of various types of biomarkers, including proteomic, genomic, epigenetic, and metabolomic markers.</div></div>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\"579 \",\"pages\":\"Article 120623\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0009898125005029\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125005029","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

男性相关因素占不孕症病例的30%，如果加上女性不孕症因素，还会增加20%。因此，诊断、预测和制定解决男性不育症的创新策略至关重要。男性不育症的评估超出了病史和体格检查，主要集中在精液分析（SA）和内分泌评估。SA评估精液的各种宏观参数，如体积、pH值、颜色和粘度。由于这些参数的显著可变性，随着时间的推移，一系列互补的生物标志物被引入。传统生物标志物在识别男性不育的潜在原因方面的有效性有限，这促使人们寻找更容易获得、更具成本效益和预测性的生殖结果标志物。新兴的组学领域，包括基因组学、蛋白质组学和代谢组学生物标志物，为男性不育症的靶向诊断提供了一条有希望的途径。本文综述了生物标志物在男性不育症中的意义。鉴于传统诊断技术的局限性，生物标志物为男性不育的潜在原因和个性化治疗的潜在途径提供了有价值的见解。本综述讨论了男性不育症的定义、患病率和病因，随后检查了各种类型的生物标志物，包括蛋白质组学、基因组学、表观遗传学和代谢组学标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Personalized biomarkers in male infertility

Male-related factors account for 30% of infertility cases and contribute an additional 20% when combined with female infertility factors. Consequently, it is crucial to diagnose, predict, and develop innovative strategies to tackle male infertility. The evaluation of male infertility extends beyond medical history and physical examination, with a primary focus on semen analysis (SA) and endocrine assessment. SA assesses various macroscopic semen parameters such as volume, pH, color, and viscosity. Because of the significant variability in these parameters, a range of complementary biomarkers has been introduced over time. The limited effectiveness of traditional biomarkers in identifying the underlying causes of male infertility has driven the search for more accessible, cost-effective, and predictive markers of reproductive outcomes. The emerging field of omics, which includes genomic, proteomic, and metabolomic biomarkers, offers a promising pathway for targeted diagnostics in male infertility. This review aims to highlight the significance of biomarkers in male infertility. Given the limitations of conventional diagnostic techniques, biomarkers provide valuable insights into the underlying causes of male infertility and potential pathways for personalized treatment. The review discusses the definition, prevalence, and etiology of male infertility, followed by an examination of various types of biomarkers, including proteomic, genomic, epigenetic, and metabolomic markers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.